Company Description

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines.

Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Psyence Biomedical Ltd.

Country	Canada
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	12
CEO	Jody Aufrichtig

Contact Details

Address: 121 Richmond Street West, Penthouse Suite 1300 Toronto, ON M5H 2K1 Canada
Phone	416-477-1708
Website	psyencebiomed.com

Stock Details

Ticker Symbol	PBM
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	1985062
CUSIP Number	74449F407
ISIN Number	CA74449F4078
SIC Code	2834

Key Executives

Name	Position
Jody Aufrichtig	Co-Founder, Executive Chairman and Chief Executive Officer
Warwick Ron Corden-Lloyd	Chief Financial Officer and Director
Dr. Neil Maresky M.D.	Global Head of Clinical Development
Taryn Vos	General Counsel

Latest SEC Filings

Date	Type	Title
Oct 5, 2026	SCHEDULE 13G	Filing
Oct 5, 2026	6-K	Report of foreign issuer
Sep 28, 2026	6-K	Report of foreign issuer
Sep 23, 2026	6-K	Report of foreign issuer
Sep 14, 2026	6-K	Report of foreign issuer
Sep 1, 2026	EFFECT	Notice of Effectiveness
Aug 26, 2026	S-8	Securities to be offered to employees in employee benefit plans
Aug 26, 2026	F-3	Filing
Aug 6, 2026	6-K	Report of foreign issuer
Jun 22, 2026	20-F	Annual and transition report of foreign private issuers

View All SEC Filings